STOCK TITAN
  1. Home
  2. Sec-filings
  3. BG
  4. [8-K] Bunge Global SA Reports Material Event

Bunge Global (NYSE: BG) furnishes Q4 and full-year 2025 results release

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Bunge Global SA filed a current report stating that it has released its financial results for the fourth quarter and full year ended December 31, 2025. The company issued a press release on February 4, 2026 to provide these results.

The press release is furnished as Exhibit 99.1 and is not treated as formally filed for liability purposes under the securities laws. The filing is mainly administrative, directing readers to the separate earnings release for detailed financial information.

Positive

  • None.

Negative

  • None.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Understanding 8-K Material Events →
0001996862false00019968622026-02-042026-02-04

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 4, 2026
Date of Report (date of earliest event reported)
___________________________________
BUNGE GLOBAL SA
(Exact name of registrant as specified in its charter)
___________________________________
Switzerland
(State of Incorporation)
000-56607
(Commission File Number)
98-1743397
(IRS Employer Identification Number)
Route de Florissant 13,
1206 Geneva, Switzerland
N.A
(Address of principal executive offices and zip code)
(Zip Code)
1391 Timberlake Manor Parkway
Chesterfield, MO
 63017
(Address of corporate headquarters )
(Zip Code)
(314) 292-2000
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Registered Shares, $0.01 par value per shareBGNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02 Results of Operations and Financial Condition     
On February 4, 2026, Bunge Global SA ("Bunge") issued a press release announcing its financial results for fourth quarter and full year ended December 31, 2025. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
In accordance with general instruction B.2 of Form 8-K, the information in this Item 2.02, including exhibits, is furnished pursuant to Items 2.02 and 9.01 and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section.

Item 9.01 Financial Statements and Exhibits
(d):     Exhibits.

Exhibit No.Description
99.1
Press Release, dated February 4, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 4, 2026


BUNGE GLOBAL SA
By:
/s/John W. Neppl
Name:
John W. Neppl
Title:
Executive Vice President, Chief Financial Officer


Source: View Original Filing on SEC EDGAR

FAQ

What did Bunge Global (BG) disclose in this 8-K filing?

Bunge Global disclosed that it released financial results for the fourth quarter and full year ended December 31, 2025. The detailed figures are contained in a separate press release furnished as Exhibit 99.1 to the report.

Which period’s results does Bunge Global (BG) cover in this disclosure?

The disclosure covers Bunge Global’s financial results for the fourth quarter and the full year ended December 31, 2025. The actual performance details are provided in the accompanying press release referenced as Exhibit 99.1.

How did Bunge Global (BG) provide its Q4 and 2025 financial results?

Bunge Global provided its Q4 and full-year 2025 financial results through a press release dated February 4, 2026. That press release is attached to the current report as Exhibit 99.1 and incorporated by reference.

Is Bunge Global’s earnings press release considered filed with the SEC?

The earnings press release is furnished, not filed, meaning it is provided for information but not subject to certain liability provisions of Section 18 of the Securities Exchange Act. The company cites the applicable instructions for this treatment.

What exhibits are included with Bunge Global’s (BG) 8-K about Q4 and 2025 results?

The 8-K includes Exhibit 99.1, which is the press release dated February 4, 2026 containing financial results, and Exhibit 104, which is the cover page interactive data file embedded within the Inline XBRL document.